Identification
- Generic Name
- Magnesium Aluminum Silicate
- DrugBank Accession Number
- DB11230
- Background
Magnesium aluminum silicate is a naturally occurring mineral obtained from silicate ores of the montmorillonite group 1. It is refined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant, and tablet binder. It also has antacid properties and is used as a component of some over the counter antacid medications.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Aluminii magnesii silicas
- Aluminium magnesium silicate
- Aluminium magnesium silicate hydrate
- Aluminium magnesium silicate polyhydrate
- Aluminum magnesium silicate
- Magnesium aluminium silicate
- Magnesium aluminium silicate hydrate
- Magnesium aluminum silicate hydrate
- External IDs
- M-907015
- MJ-2000
Pharmacology
- Indication
Magnesium aluminum silicate is used as an over the counter antacid for the self-treatment of heartburn, sour stomach, or acid indigestion Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Magnesium aluminum silicate neutralizes excess acid in the stomach to reduce or eliminate symptoms of heartburn, sour stomach, or acid indigestion Label
- Mechanism of action
Magnesium aluminum silicate reacts with acid in the stomach to increase the pH.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The LD50 in mice is considered to be >50000 mg/kg with oral suspensions of magnesium aluminum silicate 1. The dermal LD50 is considered to be >3.5 g/kg observed in rabbits. Magnesium aluminum silicate produced mild skin irritation. In a 90 day study in rats, animal fed a diet with 20% magnesium aluminum silicate had slightly stunted growth. With 5% and 10% the rats had increased silicone content in the spleen. At 2% one male rat died and at 10% one male and female rat died. These rats had fibrous exudates in the thorax and hemorrhage in the lungs with evidence of infection. No evidence of teratogenicity or mutagenicity was found in the appropriate studies.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAtracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium Aluminum Silicate. Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium Aluminum Silicate. Botulinum toxin type A The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium Aluminum Silicate. Botulinum toxin type B The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type B. Capreomycin The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium Aluminum Silicate. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Veegum
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6M3P64V0NC
- CAS number
- 1327-43-1
References
- General References
- Elmore AR: Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. Int J Toxicol. 2003;22 Suppl 1:37-102. [Article]
- External Links
- FDA label
- Download (306 KB)
- MSDS
- Download (47 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Insoluble MSDS - Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at January 07, 2021 03:13